BioAtla, Inc. (BCAB)
OTCMKTS · Delayed Price · Currency is USD
1.080
-0.610 (-36.09%)
At close: Sep 1, 2026
BioAtla Employees
BioAtla had 41 employees as of December 31, 2025. The number of employees decreased by 20 or -32.79% compared to the previous year.
Employees
41
Change (1Y)
-20
Growth (1Y)
-32.79%
Revenue / Employee
$207,317
Profits / Employee
-$767,171
Market Cap
1.80M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 41 | -20 | -32.79% |
| Dec 31, 2024 | 61 | -4 | -6.15% |
| Dec 31, 2023 | 65 | -1 | -1.52% |
| Dec 31, 2022 | 66 | 10 | 17.86% |
| Dec 31, 2021 | 56 | 20 | 55.56% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| CASI Pharmaceuticals | 214 |
| International Stem Cell | 33 |
| Vaccinex | 27 |
| AccuStem Sciences | 4 |
| Bioxytran | 2 |
BioAtla News
- 3 months ago - Context Therapeutics enters license agreement amendment with BioAtla - TheFly
- 5 months ago - BioAtla trading halted, news pending - TheFly
- 5 months ago - BioAtla announces 50-for-1 share consolidation - TheFly
- 5 months ago - BioAtla Announces Share Consolidation - GlobeNewsWire
- 5 months ago - BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - GlobeNewsWire
- 6 months ago - BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets - GlobeNewsWire
- 8 months ago - BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) - GlobeNewsWire
- 10 months ago - BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing - GlobeNewsWire